Worth reading
27Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
58815
¥ thousands (year-on-year improvement in operating loss)Wording
Conditional
How definitive the wording is.Contents of this document
Financial results presentationFirst quarter of the fiscal year ending December 20263 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales186,984 US dollars in parentheses: ¥29.990 million
Operating profit-2,835,806 US dollars in parentheses: ¥454.834 million operating loss
Net income-2,586,258 US dollars in parentheses: ¥414.809 million net loss; quarterly net loss
Results for the three months of the current quarterFor the 3 months of the first quarter of the fiscal year ending December 2026: operating revenue of US$186,984 (¥29.990 million), an operating loss of US$2,835,806 (¥454.834 million), and a quarterly net loss of US$2,586,258 (¥414.809 million)
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Operating revenue: +US$186,984 (+¥29.990 million); R&D and patent expenses: −US$577,288 (−¥92.591 million); general and administrative expenses: +US$227,467 (+¥36.483 million); service costs: +US$170,101 (+¥27.282 million); total operating expenses: −US$179,720 (−¥28.825 million); operating income: +US$366,704 (+¥58.815 million); interest income: −US$83,147 (−¥13.335 million); quarterly net loss: +US$277,862 (+¥44.566 million)
New initiatives
The company plans to newly develop MN-166 for brain metastases from solid tumors. It plans to advance clinical research in collaboration with CNIO and Dr. Valiente and others who led the research. The ALS Expanded Access Program is currently underway with total funding of US$22 million (approximately ¥3.5 billion) from the NIH.Number of stores and locations
Clinical trial patient enrollment sites: 12 sites| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | First quarter of the fiscal year ending December 2026 |
| Net Sales | 186,984 US dollars (in parentheses: ¥29.990 million) |
| Operating profit | -2,835,806 US dollars (in parentheses: ¥454.834 million operating loss) |
| Net income | -2,586,258 US dollars (in parentheses: ¥414.809 million net loss; quarterly net loss) |
| Results for the three months of the current quarter | For the 3 months of the first quarter of the fiscal year ending December 2026: operating revenue of US$186,984 (¥29.990 million), an operating loss of US$2,835,806 (¥454.834 million), and a quarterly net loss of US$2,586,258 (¥414.809 million) |
| Breakdown of Factors Affecting the Change | Operating revenue: +US$186,984 (+¥29.990 million); R&D and patent expenses: −US$577,288 (−¥92.591 million); general and administrative expenses: +US$227,467 (+¥36.483 million); service costs: +US$170,101 (+¥27.282 million); total operating expenses: −US$179,720 (−¥28.825 million); operating income: +US$366,704 (+¥58.815 million); interest income: −US$83,147 (−¥13.335 million); quarterly net loss: +US$277,862 (+¥44.566 million) |
| Number of stores and locations | Clinical trial patient enrollment sites: 12 sites |
| New initiatives | The company plans to newly develop MN-166 for brain metastases from solid tumors. It plans to advance clinical research in collaboration with CNIO and Dr. Valiente and others who led the research. The ALS Expanded Access Program is currently underway with total funding of US$22 million (approximately ¥3.5 billion) from the NIH. |
Items this document does not state (22)
Ordinary incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsKey KPIsUnit price and quantity metricsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company presents operating revenue, R&D and patent expenses, general and administrative expenses, service costs and other profit and loss items, together with their year-on-year changes, but does not explain the specific reasons behind those changes. Regarding its R&D projects, the company explains that the ALS Expanded Access Program has reached 50% of its target patient enrollment and that research results on ibudilast were published in an international medical journal.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.